Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A vs Phosphatidylserine: they're closely matched on evidence (6 vs 6/10); they're alternatives for improve memory & learning — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Huperzine A and Phosphatidylserine are closely matched across evidence, studies, and safety.
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Huperzine A and Phosphatidylserine have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
100-300mg daily
With meals, Evening or post-workout for cortisol
Soy or sunflower-derived phosphatidylserine
and 1 more not shown
2-4 weeks
30-60 minutes
2-4 weeks
During use
4-12 weeks
2 weeks
4-8 weeks
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=70
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial
Journal of affective disorders (2025) · Rct · n=190
The capsule combined phosphatidylserine (63 mg/day) with α-linolenic acid, ginkgo flavonoids, vitamins B1 and B6 and folic acid, taken for 12 months. The effect cannot be credited to phosphatidylserine alone.
Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial
Dementia and geriatric cognitive disorders (2010) · Rct · n=157
157 participants were randomized to receive either PS-DHA or placebo for 15 weeks.
Phosphatidylserine for the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis
Journal of alternative and complementary medicine (2021) · Meta analysis · n=216
Four studies met the inclusion criteria for the narrative review (n = 344) and three for the meta-analysis (n = 216).
Doses are per day. At 200 mcg (0.1 mg twice daily), a double-blind trial in 78 people with mild to moderate vascular dementia improved MMSE, CDR and daily living scores over 12 weeks (PMID 21833673). At 400 mcg (200 mcg twice daily), the primary analysis of a phase II trial in 210 people with Alzheimer's disease found no effect on ADAS-Cog at 16 weeks, so the curve stays flat rather than rising (PMID 21502597). At 800 mcg (400 mcg twice daily), the same trial found a 2.27-point ADAS-Cog gain at 11 weeks that was no longer significant at 16 weeks. A meta-analysis of four trials using 300 to 500 mcg a day found MMSE and daily living gains (PMID 19221692). The trials are in different populations and only one compared doses, so no minimum, optimal or safe ceiling is set.
The dose points come from one randomised, double-blind trial of 78 Japanese adults aged 50 to 69 with memory complaints (PMID 21103034), who took 100 mg or 300 mg a day of soy-derived phosphatidylserine or placebo for 6 months. Test scores rose similarly in all groups, placebo included, so neither dose is shown to beat placebo. Memory scores rose from baseline on both doses only in people with low baseline scores, a within-group result. No side effects and no change in blood markers were seen, which is why the ceiling is 300 mg. The PS-DHA memory trial (PMID 20523044, 157 older adults) states no dose, the 190-person trial in mild cognitive impairment (PMID 39317299) gave 63 mg inside a multi-ingredient capsule, and the pooled 200 to 300 mg effect on inattention (PMID 33539192) is in children with ADHD, so none of them can sit on this curve.
AI-estimated from published studies. Interpret as directional guidance.
Both Huperzine A and Phosphatidylserine are closely matched — the best choice depends on your specific health goals.
For improve memory & learning, Phosphatidylserine has a higher relevance score (80 vs 72).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.